How do biotechs build a defensible data moat?
Costs keep doubling while approvals don't, how do I turn continuous monitoring into portfolio decisions and a moat that actually compounds?
Pharma R&D spend has roughly doubled in a decade while output holds near ~50 drugs a year at under 10% success: Eroom's law. We used Hydra to connect continuous monitoring to strategy: surfacing white space, pressure-testing direction, and compounding proprietary data into a self-improving moat that strengthens with every experiment.
Who this is for: Executives, business-development, and strategy leaders shaping portfolio direction and building a defensible data moat.
- R&D spend growth in a decade (Eroom's law)
- ~2×
- clinical success rate the strategy must beat
- <10%
- every experiment sharpens the next decision
- self-improving
R&D spend growth in a decade (Eroom's law)
clinical success rate the strategy must beat
every experiment sharpens the next decision
Why monitoring alone doesn't move the needle
The backdrop is Eroom's law: large-pharma R&D spend has roughly doubled over ten years, yet the industry still delivers around fifty drugs a year at a success rate below ten percent. Costs keep doubling; approvals don't. Against that headwind, simply tracking the landscape isn't enough.
The strategic questions are what to do with the monitoring: where is the unaddressed need, which direction is defensible, and how does today's data make tomorrow's position stronger rather than just better-informed? For a company raising capital, that defensibility is the entire story, investors price a compounding asset very differently from one that merely runs studies.
What teams in this space search for
- How do biotechs build a defensible data moat?
- How do I find white space in oncology?
- Why does drug R&D keep getting more expensive (Eroom's law)?
How we solved it with Hydra
“Using the live landscape and our proprietary data, surface white space, subpopulations and indications with poor current options, and pressure-test where our programmes are exposed. Route unmet-need signals back into discovery, and capture each result so the next analysis starts smarter than the last.”
What Hydra ran
Hydra tied the live competitive view to strategy: it surfaced subpopulations and indications with poor current options (white space), pressure-tested where a programme is exposed, and routed unmet-need signals back into discovery.
Each pass enriched the proprietary context it works from, so the system improves with use, the discovery work that can't be reduced to fixed rules (which confounder, which subgroup, which edge to trust) is exactly where a learning loop with a human in the loop beats a static script.
What it found
The compounding is the moat. Data plus a self-improving loop turns proprietary science into an edge that widens over time, because the value isn't a single model, it's the loop, which a competitor without your data and history can't easily replicate.
What we learned
Static analysis pipelines go stale: new data and cohorts move the target, and what's signal in one tumour type is noise in another. A learning loop handles that contingency instead of decaying.
That compounding edge is precisely the defensibility that strengthens a fundraise, a portfolio whose data sharpens the next decision is a fundamentally different asset from one that just runs studies.
What you get
- White-space and unmet need surfaced from a live, subtype-level landscape view
- Programme exposure pressure-tested before resources are committed
- Proprietary data compounded into a self-improving advantage
- A defensibility narrative grounded in a compounding loop, not a single model
Data sources used
- ClinicalTrials.gov & published outcomes (landscape)
- cBioPortal / TCGA (biomarker & subtype context)
- Your proprietary data (compounded over time)
Figures reflect analyses PharosBio ran on public datasets and public benchmarks. Named competitors, collaborators, and logos are withheld at this stage; the methods and results shown are real and repointable to your own target.
Sources & methods
- Eroom's law: Scannell et al., Nat Rev Drug Discov 2012
- Software 2.0 framing: Karpathy, 2017
Frequently asked questions
What is Eroom's law and why does it matter to strategy?
Eroom's law is the decades-long fall in drug-discovery productivity despite rising investment: R&D spend has roughly doubled in ten years while output holds near ~50 drugs a year at under 10% success. It's the headwind any portfolio strategy has to beat.
What does 'data moat' actually mean here?
Your proprietary data, run through a self-improving loop, produces an advantage that widens with use, each experiment sharpens the next decision. Because the value is the compounding loop rather than one model, a competitor without your data and history can't easily catch up.
Run this analysis on your question
Hydra plans, executes, and validates, so you reach a defensible answer in hours, not weeks.